Radiological signature of HER2-Positive gallbladder cancer: analysis of CT features
Authors:
- Pankaj GuptaPGPankaj Gupta
- Niharika DuttaNDNiharika Dutta
- Shravya SinghSSShravya Singh
- Nikita PradhanNPNikita Pradhan
- Ruby SiddiquiRSRuby Siddiqui
- Ajay GulatiAGAjay Gulati
- Naveen KalraNKNaveen Kalra
- Gaurav PrakashGPGaurav Prakash
- Thakur YadavTYThakur Yadav
- Lileswar KamanLKLileswar Kaman
- Santosh IrrinkiSISantosh Irrinki
- Harjeet SinghHSHarjeet Singh
- 3 July 2025
- journal article
- research article
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (2) , 660-672
Abstract
Objective This study aimed to identify distinctive computed tomography (CT) features associated with human epidermal growth factor receptor 2 (HER2) status in gallbladder cancer (GBC) that could serve as noninvasive imaging biomarkers. Materials and methods This study included 213 patients with pathologically confirmed GBCs with availability of HER2 status (171 HER2-negative, 42 HER2-positive). Pre-treatment contrast-enhanced CT scans were evaluated by two radiologists blinded to HER2 status. Multivariate analysis was performed using logistic regression with L2 regularization. Model discrimination was assessed using receiver operating characteristic (ROC) analysis, and internal validation was performed using bootstrap resampling (1,000 iterations) to correct for optimism. Results HER2-positive tumors exhibited larger lymph nodes (1.93 ± 0.79 cm vs. 1.61 ± 0.61 cm, p = 0.015), less frequent gallstones (14.3% vs. 35.7%, p = 0.013), arterial phase hyperenhancement (20.0% vs. 44.1%, p = 0.026), mass-like morphology (35.7% vs. 55.6%, p = 0.033), and more frequent biliary compression by lymph nodes (19.0% vs. 4.1%, p = 0.002). Multivariate analysis identified biliary compression by lymph nodes as the strongest positive predictor of HER2 positivity [odds ratio (OR) 2.99, 95% CI: 1.25–7.04], while arterial phase hyperenhancement (OR 0.40, 95% CI: 0.19–0.75), gallstone presence (OR 0.40, 95% CI: 0.18–0.75), and mass-like morphology (OR 0.54, 95% CI: 0.29–0.95) were significant negative predictors. The model demonstrated good discrimination (area under the ROC curve 0.782) with sensitivity 75%, specificity 79.4%, and negative predictive value 96.2%. Conclusion HER2-positive GBCs display characteristic CT findings that can be utilized for noninvasive diagnosis with robust predictive performance.Keywords
Funding Information
- Radiological Society of North America (RSD2208)
This publication has 15 references indexed in Scilit:
- Gallbladder cancerNature Reviews Disease Primers, 2022
- Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket studyThe Lancet Oncology, 2021
- Dynamic contrast-enhanced breast MRI features correlate with invasive breast cancer angiogenesisnpj Breast Cancer, 2021
- Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancerScientific Reports, 2020
- Anti-Her2neu directed therapy in advanced gall bladder cancer: A prospective, multicenter experience from India.Journal of Clinical Oncology, 2020
- Lymphovascular invasion in breast cancer is associated with gene expression signatures of cell proliferation but not lymphangiogenesis or immune responseBreast Cancer Research and Treatment, 2020
- Tumor angiogenesis: causes, consequences, challenges and opportunitiesCellular and Molecular Life Sciences, 2019
- New Horizons for Precision Medicine in Biliary Tract CancersCancer Discovery, 2017
- HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical OncologyJournal of Clinical Oncology, 2017
- HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancerAnnals of Oncology, 2009